Skip to main content

Consumer Genomics Startup Navigenics Makes Official Debut; Names Sue Siegel as Director

NEW YORK (GenomeWeb News) — Navigenics, a Bay Area company focused on using whole-genome scanning to identify an individuals’ genetic risks for certain diseases, today said it has made its official debut as a company.
 
The firm said it has also secured a Series B round of venture capital financing for an undisclosed amount, bringing its total funding to $25 million to date.
 
The company, which has named as a director former Affymetrix President Sue Siegel, said it will initially use saliva-based tests and genome scans to “help people understand their genetic predisposition to disease and arm them with the information about what actions to take.” Siegel is a partner with MDV-Mohr Davidow Ventures, which participated in the round.
 
Beside MDV-Mohr Davidow Ventures, Navigenics said participants in the financing included Kleiner Perkins Caufield & Byers and Sequoia Capital.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.